Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19

Fig. 1

VERO-E6 cells infected by SARS-CoV-2 across different treatment groups (100 ×). To 180 mL of healthy human plasma, 20 mL of indicator virus was added at a 9: 1 (V: V) ratio, and mixed. Methylene blue (MB) was added to 200 mL of plasma virus mixture and mixed to a final concentration of 1 μM (a), 2 μM (b), or 4 (c) μM. The “BX-1 AIDS treatment instrument” was used at room temperature, the illumination adjusted to 55,000 ± 0.5 million Lux, and irradiation was carried out for 40 mins under single wavelength 630-nm light. The virus control (d) was set (only virus in the plasma, left at room temperature for 40 mins as an untreated control), and control with pure 1 μM MB (e) was set (virus and 1 μM MB added to the plasma, with no light treatment, and allowed to stand for 40 mins as a control for the effect of MB on the virus). Finally, the light-only control (f) was set (only the virus was added to the plasma, and light was used for 40 mins as a control of the effect of light on virus). This experiment was repeated three times

Back to article page